Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Liabilities (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Total Liabilities data on record, last reported at $102.5 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 23.3% year-over-year to $102.5 million; the TTM value through Dec 2025 reached $102.5 million, down 23.3%, while the annual FY2025 figure was $102.5 million, 23.3% down from the prior year.
  • Total Liabilities reached $102.5 million in Q4 2025 per CCCC's latest filing, down from $111.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $151.0 million in Q1 2022 and bottomed at $102.5 million in Q4 2025.
  • Average Total Liabilities over 5 years is $127.8 million, with a median of $131.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: skyrocketed 36.86% in 2022, then fell 23.3% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $117.2 million in 2021, then rose by 20.87% to $141.6 million in 2022, then dropped by 7.96% to $130.3 million in 2023, then increased by 2.52% to $133.6 million in 2024, then dropped by 23.3% to $102.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $102.5 million in Q4 2025, $111.1 million in Q3 2025, and $122.5 million in Q2 2025.